×
About 473 results

ALLMedicine™ Myeloproliferative Disease Center

Research & Reviews  169 results

Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chr...
https://doi.org/10.1007/s12032-022-01714-y 10.1016/j.cellsig.2013.05.019 10.1111/j.1349-7006.2012.02346.x 10.2147/dddt.S80207 10.1002/ajh.25011 10.2147/tcrm.s3425 10.1371/journal.pone.0098859 10.1016/j.clml.2013.05.012 10.2147/dddt.S85050 10.1007/s40272-018-0319-8 10.1182/blood.V101.2.690 10.1182/blood-2007-08-109330 10.1182/blood-2009-10-248211 10.4161/cc.22387 10.1158/2159-8290.Cd-14-1490 10.4161/cc.22808 10.1128/mcb.01484-13 10.1016/j.tcb.2003.11.001 10.1038/srep44674 10.1016/j.critrevonc.2018.05.003 10.1158/0008-5472.Can-06-1586 10.1182/blood-2011-11-394346 10.1182/blood-2010-08-303099 10.1002/ajh.21380 10.1007/s13277-015-4015-9 10.3747/co.v18i2.391 10.1002/ajh.24423 10.1016/j.leukres.2010.04.016 10.5732/cjc.011.10327 10.1016/j.bbamcr.2013.06.028 10.7150/ijms.29134 10.7508/ibj.2016.01.009 10.4161/23723556.2014.975089 10.1074/jbc.M212328200 10.1186/s12890-015-0127-7 10.1038/s41598-017-03814-6 10.1038/cdd.2014.116 10.1038/nrm2199 10.4161/cbt.5.7.2969 10.1038/sj.cdd.4401984 10.1016/j.bbrc.2018.09.032 10.1369/jhc.5A6785.2005 10.1074/jbc.M704069200 10.3390/cancers10100344 10.18632/oncotarget.13086 10.1158/0008-5472.Can-07-0045 10.1053/j.gastro.2018.10.031 10.1038/s41467-019-13700-6 10.1155/2015/324815 10.1182/bloodadvances.2018020503
Medical Oncology (Northwood, London, England); Ozel B, Kipcak S et. al.

Jun 19th, 2022 - Chronic myeloid leukemia (CML) is a myeloproliferative disease that mediated by BCR/ABL oncogenic signaling. CML can be targeted with the imatinib, dasatinib, and nilotinib TKI inhibitors, the latter two of them have been approved for imatinib-res...

Pediatric Myelodysplastic Syndrome
https://emedicine.medscape.com/article/988024-overview

Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...

Pediatric Myelodysplastic Syndrome
http://emedicine.medscape.com/article/988024-overview

Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...

Pediatric Myelodysplastic Syndrome
https://emedicine.medscape.com/article/1976592-overview

Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...

Pediatric Myelodysplastic Syndrome
https://emedicine.medscape.com/article/988024-print

Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...

see more →

Guidelines  1 results

Prophylaxis and management of venous thromboembolism in patients with myeloproliferativ...
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.

Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...

see more →

Clinicaltrials.gov  13 results

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
https://clinicaltrials.gov/ct2/show/NCT04146038

May 17th, 2022 - PRIMARY OBJECTIVE: I. Determine the tolerability of the addition of standard dose salsalate to the standard treatment combination of venetoclax + hypomethylating agent (HMA) (decitabine or azacitidine [5-azacytidine]). SECONDARY OBJECTIVES: I. Det...

MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
https://clinicaltrials.gov/ct2/show/NCT04994158

Aug 6th, 2021 - Splanchnic or abdominal vein thrombosis (SVT) comprises thrombosis of hepatic, portal, superior mesenteric, splenic vein in isolation or combination. It has a prevalence of 1-2% in the general population based on autopsy reports. However, 40-50% o...

Effect of Pharmacogenetics on Imatinib Plasma Level and Response
https://clinicaltrials.gov/ct2/show/NCT03262974

Aug 3rd, 2021 - Introduction: Chronic myeloid leukaemia (CML) is a myeloproliferative disease with an incidence of one to two cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. The introduction of imatinib,...

Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT
https://clinicaltrials.gov/ct2/show/NCT03977103

Jan 13th, 2020 - Improving cGvHD/disease free survival in patients with high-risk acute leukemias or other hematologic malignancy where HSCT is indicated with the use of a regulatory T cell based protocol. Hyper-fractionated Total Body Irradiation or Total Marrow ...

Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL
https://clinicaltrials.gov/ct2/show/NCT04053933

Aug 13th, 2019 - Study type An observational study conducted in different hematological centers in Belgium. Study objectives Primary objective: To assess the impact of newly started treatments on the QOL of patients suffering from myelodysplastic syndromes. Second...

see more →

News  6 results

Breaking Down the Epidemiology of AML
https://www.onclive.com/view/breaking-down-the-epidemiology-of-aml

Apr 2nd, 2021 - Transcript: Richard F. Schlenk, MD: Acute myeloid leukemia [AML] is a hematological disease focused on myeloid cells. It’s characterized by different mutations, which occur in the hematopoietic stem cells but also the hematopoietic progenitor ...

Somatic Mutations Could Predict Response to Hypomethylating Agents in MDS
https://www.onclive.com/view/somatic-mutations-could-predict-response-to-hypomethylating-agents-in-mds

Dec 20th, 2020 - Aziz Nazha, MD A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes (MDS), according to findings from a small p...

Switch may increase supply of HSCs from cord blood
https://www.mdedge.com/hematology-oncology/article/187211/transplantation/switch-may-increase-supply-hscs-cord-blood
HT Staff

Jul 15th, 2016 - Cord blood donation Photo courtesy of NHS Researchers have discovered a genetic switch that could increase the supply of hematopoietic stem cells (HSCs) derived from cord blood, according to a paper published in Cell Stem Cell. However, experiment.

A Simple, Rapid, and Sensitive Method for the Detection of the JAK2 V617F Mutation
https://www.medscape.com/viewarticle/558906_3

Results Optimization The important variables for the ACB-PCR assay to detect the V617F mutation were the annealing temperature, dNTP concentration, and primer concentration. The majority of the conditions were modeled from a previous ACB-PCR assay...

A Simple, Rapid, and Sensitive Method for the Detection of the JAK2 V617F Mutation
https://www.medscape.com/viewarticle/558906_1

Abstract and Introduction Abstract The point mutation 1849 (GAET) V617F in the JAK2gene occurs at high frequency in several chronic myeloproliferative diseases. Although a number of V617F mutation detection methods have been described, few are rea...

see more →